Pharmaceutical composition with improved stability for topical intranasal application for the treatment of rhinitis, wherein the composition is present as an aqueous composition and wherein the composition contains: a) at least one imidazoline-based alpha-sympathomimetic or a physiologically acceptable salt thereof, wherein the imidazoline-based alpha-sympathomimetic is selected from xylometazoline; and b) pantothenol; characterized in that the pH of the composition is adjusted and/or kept constant in the range of from 5.2 to 5.9, the pH of the composition being adjusted and/or kept constant by means of at least one chemical buffer system, the chemical buffer system used being a dihydrogen phosphate/monohydrogen posphate buffer system, the dihydrogen phosphate/mono hydrogen posphate buffer system having a dihydrogen phosphate/mono hydrogen posphate molar ratio in the range of from 6: 1 to 110: 1 is used; that the composition contains a content of degradation product(s) of the active ingredient a), in particular impurity A, of at most 5% by weight, based on the active ingredient a), even after storage of the composition at temperatures in the range of from 20 °C to 50 °C, at a pressure of 1,013.25 mbar and at a relative humidity in the range of from 50% to 90% for at least 6 months; and that the composition contains a content of degradation product(s) of the active ingredient b), in particular aminopropanol and/or D-pantolactone, of at most 5% by weight in each case, based on the active ingredient b), even after storage of the composition at temperatures in the range of from 20 °C to 50 °C, at a pressure of 1,013.25 mbar and at a relative humidity in the range of from 50% to 90% for at least 6 months. wherein the composition is present as an aqueous composition and wherein the composition contains: a) at least one imidazoline-based alpha-sympathomimetic or a physiologically acceptable salt thereof, wherein the imidazoline-based alpha-sympathomimetic is selected from xylometazoline; and b) pantothenol; a) at least one imidazoline-based alpha-sympathomimetic or a physiologically acceptable salt thereof, wherein the imidazoline-based alpha-sympathomimetic is selected from xylometazoline; and b) pantothenol; characterized in that the pH of the composition is adjusted and/or kept constant in the range of from 5.2 to 5.9, the pH of the composition being adjusted and/or kept constant by means of at least one chemical buffer system, the chemical buffer system used being a dihydrogen phosphate/monohydrogen posphate buffer system, the dihydrogen phosphate/mono hydrogen posphate buffer system having a dihydrogen phosphate/mono hydrogen posphate molar ratio in the range of from 6: 1 to 110: 1 is used; that the composition contains a content of degradation product(s) of the active ingredient a), in particular impurity A, of at most 5% by weight, based on the active ingredient a), even after storage of the composition at temperatures in the range of from 20 °C to 50 °C, at a pressure of 1,013.25 mbar and at a relative humidity in the range of from 50% to 90% for at least 6 months; and that the composition contains a content of degradation product(s) of the active ingredient b), in particular aminopropanol and/or D-pantolactone, of at most 5% by weight in each case, based on the active ingredient b), even after storage of the composition at temperatures in the range of from 20 °C to 50 °C, at a pressure of 1,013.25 mbar and at a relative humidity in the range of from 50% to 90% for at least 6 months.